Heart failure mortality according to acute variations in N-terminal pro B-type natriuretic peptide and cystatin C levels

Journal of Cardiovascular Medicine

Volumn 15, Issue 2, 2014, Pages 115-121

  Carrasco Sánchez, Francisco J ^a   Pérez Calvo, Juan I ^b   Morales Rull, José L ^b   Galisteo Almeda, Luis ^a   Páez Rubio, Inmaculada ^a   Barón Franco, Bosco ^a   Aguayo Canela, Mariano ^a   Pujol De La Llave, Emilio ^a  

^a HOSPITAL JUAN RAMÓN JIMÉNEZ   (Spain)

^b HOSPITAL CLÍNICO UNIVERSITARIO LOZANO BLESA   (Spain)

Author keywords

cystatin C; heart failure; mortality; N terminal pro B type natriuretic peptide; prognosis; variations

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; CYSTATIN C;

ACUTE HEART FAILURE; ADULT; AGED; ANALYSIS; ANEMIA; ARTICLE; BLOOD LEVEL; FEMALE; FOLLOW UP; HAZARD RATIO; HOSPITAL ADMISSION; HOSPITALIZATION; HUMAN; HYPONATREMIA; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MEDICAL INFORMATION; MORTALITY; OBSERVATIONAL STUDY; PROGNOSIS; STATISTICS; VERY ELDERLY;

AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; CHI-SQUARE DISTRIBUTION; CYSTATIN C; FEMALE; HEART FAILURE; HOSPITALIZATION; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MULTIVARIATE ANALYSIS; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RISK FACTORS; SPAIN; TIME FACTORS; UP-REGULATION;

EID: 84896698521     PISSN: 15582027     EISSN: 15582035     Source Type: Journal    
DOI: 10.2459/JCM.0b013e3283654bab     Document Type: Article

References (30)

1. Braunwald E. Biomarkers in heart failure. N Engl J Med 2008; 358:2148-2159.
2. Anwaruddin S, Lloyd-Jones DM, Baggish A, et al. Renal function, congestive heart failure, and amino-terminal pro-brain natriuretic peptide measurement: results from the ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) Study. JAmColl Cardiol 2006; 47:91-97.
3. Lainchbury JG, Troughton RW, Strangman KM, et al. N-terminal pro-B-type natriuretic peptide-guided treatment for chronic heart failure: results fromthe BATTLESCARRED (NT-proBNP-Assisted Treatment to Lessen Serial Cardiac Readmissions and Death) trial. J Am Coll Cardiol 2009; 55:53-60.
4. Pfisterer M, Buser P, Rickli H, et al. BNP-guided vs symptom-guided heart failure therapy: the Trial of Intensified vs Standard Medical Therapy in Elderly Patients with Congestive Heart Failure (TIME-CHF) randomized trial. JAMA 2009; 301:383-392.
5. Shah MR, Califf RM, Nohria A, et al. The STARBRITE trial: a randomized, pilot study of B-type natriuretic peptide-guided therapy in patients with advanced heart failure. J Card Fail 2011; 17:613-621.
6. Di Somma S, Magrini L, Pittoni V, et al. In-hospital percentage BNP reduction is highly predictive for adverse events in patients admitted for acute heart failure: the Italian RED study. Crit Care 2010; 14:R116.
7. Bettencourt P, Azevedo A, Pimenta J, et al. N-terminal-pro-brain natriuretic peptide predicts outcome after hospital discharge in heart failure patients. Circulation 2004; 110:2168-2174.
8. Michtalik HJ, Yeh HC, Campbell CY, et al. Acute changes in N-terminal pro-B-type natriuretic peptide during hospitalization and risk of readmission and mortality in patients with heart failure. Am J Cardiol 2011; 107:1191-1195.
9. Lassus JP, Nieminen MS, Peuhkurinen K, et al. Markers of renal function and acute kidney injury in acute heart failure: definitions and impact on outcomes of the cardiorenal syndrome. Eur Heart J 2010; 31:2791-2798.
10. Lassus J, Harjola VP, Sund R, et al. Prognostic value of cystatin C in acute heart failure in relation to other markers of renal function and NT-proBNP. Eur Heart J 2007; 28:1841-1847.
11. Carrasco-Sanchez FJ, Galisteo-Almeda L, Paez-Rubio I, et al. Prognostic value of cystatin C on admission in heart failure with preserved ejection fraction. J Card Fail 2011; 17:31-38.
12. Perez-Calvo JI, Ruiz-Ruiz FJ, Carrasco-Sanchez FJ, et al. Prognostic value of serum cystatinC and N-terminal pro B-type natriuretic peptide in patients with acute heart failure. Eur J Intern Med 2012; 23:599-603.
13. Lassus J, Harjola VP, Cystatin C. A step forward in assessing kidney function and cardiovascular risk. Heart Fail Rev 2012; 17:251-261.
14. Dickstein K, Cohen-Solal A, Filippatos G, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J 2008; 29:2388-2442.
15. Levey AS, Coresh J, Greene T, et al. Expressing the Modification of Diet in Renal Disease Study equation for estimating glomerular filtration rate with standardized serum creatinine values. Clin Chem 2007; 53:766-772.
16. Ferreira S, Almeida R,Guerrero H, et al. Prognosis of decompensated heart failure: role of NT-proBNP. Rev Port Cardiol 2007; 26:535-545.
17. Bettencourt P, Azevedo A, Fonseca L, et al. Prognosis of decompensated heart failure patients with preserved systolic function is predicted by NTproBNP variations during hospitalization. Int J Cardiol 2007; 117:75-79.
18. Pimenta JM, Almeida R, Araujo JP, et al. Amino terminal B-type natriuretic peptide, renal function, and prognosis in acute heart failure: a hospital cohort study. J Card Fail 2007; 13:275-280.
19. O'Brien RJ, Squire IB, Demme B, Davies JE, Ng LL. Predischarge, but not admission, levels of NT-proBNP predict adverse prognosis following acute LVF. Eur J Heart Fail 2003; 5:499-506.
20. Waldo SW, Beede J, Isakson S, et al. Pro-B-type natriuretic peptide levels in acute decompensated heart failure. J Am Coll Cardiol 2008; 51:1874-1882.
21. Masson S, Latini R, Anand IS, et al. Prognostic value of changes in N-terminal pro-brain natriuretic peptide in Val-HeFT (Valsartan Heart Failure Trial). J Am Coll Cardiol 2008; 52:997-1003.
22. Bettencourt P, Januzzi JL Jr. Amino-terminal pro-B-type natriuretic peptide testing for inpatient monitoring and treatment guidance of acute destabilized heart failure. Am J Cardiol 2008; 101:67-71.
23. Di Somma S, Magrini L, Tabacco F, et al. Brain natriuretic peptide and N-terminal pro-B-type natriuretic peptide show a different profile in response to acute decompensated heart failure treatment. Congest Heart Fail 2008; 14:245-250.
24. Goei D, van Kuijk JP, Flu WJ, et al. Usefulness of repeated N-terminal pro-Btype natriuretic peptide measurements as incremental predictor for longterm cardiovascular outcome after vascular surgery. Am J Cardiol 2011; 107:609-614.
25. Perez-Calvo JI, Montero-Perez-Barquero M, Camafort-Babkowski M, et al. Influence of admission blood pressure on mortality in patients with acute decompensated heart failure. QJM 2011; 104:325-333.
26. Casado J, Montero M, Formiga F, et al. Renal function in patients with heart failure: prognostic value. Rev Clin Esp 2012; 212:119-126.
27. Smith GL, Lichtman JH, Bracken MB, et al. Renal impairment and outcomes in heart failure: systematic review and meta-analysis. J Am Coll Cardiol 2006; 47:1987-1996.
28. Roos JF, Doust J, Tett SE, Kirkpatrick CM. Diagnostic accuracy of cystatin C compared to serum creatinine for the estimation of renal dysfunction in adults and children: a meta-analysis. Clin Biochem 2007; 40:383-391.
29. Shlipak MG, Sarnak MJ, Katz R, et al. Cystatin C and the risk of death and cardiovascular events among elderly persons. N Engl J Med 2005; 352:2049-2060.
30. Manzano-Fernandez S, Januzzi JL Jr, Boronat-Garcia M, et al. Beta-trace protein and cystatin C as predictors of long-term outcomes in patients with acute heart failure. J Am Coll Cardiol 2011; 57:849-858.